https://www.pharmaradar360.com/article/cbdb2b4abcfa6e23Pharma Surgeen2026-05-15T11:00:01.000ZAndrea Pfeifer ends 23-year reign at AC Immune; Acadia's top R&D exec announces retirementhttps://www.pharmaradar360.com/article/ba176a9cba0434bbPharma Surgeen2026-05-15T10:58:05.000ZKielipankissa: Milla Uusitupahttps://www.pharmaradar360.com/article/647f82b93b4825e4Pharma Surgeen2026-05-15T10:45:33.000Z#ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes livehttps://www.pharmaradar360.com/article/478820741b8a8bd0Pharma Surgeen2026-05-15T10:43:01.000ZPresident Ramaphosa honours SU academics for global contributions to healing and sciencehttps://www.pharmaradar360.com/article/f71d1f76db23bce7Pharma Surgeen2026-05-15T10:32:07.000ZBiopharma industry endorses Pazdur for FDA commissioner rolehttps://www.pharmaradar360.com/article/1680b0a5c5836382Pharma Surgeen2026-05-15T10:23:34.000ZBiogen forges on with Alzheimer’s therapy development despite Phase II misshttps://www.pharmaradar360.com/article/645a788df5c6fee8Pharma Surgeen2026-05-15T10:04:00.000ZInscrivez-vous au diplôme universitaire sur la recherche en soinshttps://www.pharmaradar360.com/article/38317374b8e38f24Pharma Surgeen2026-05-15T10:00:17.000ZDigital Health’s monthly roundup of contracts and go liveshttps://www.pharmaradar360.com/article/e797e37b5c19e3f1Pharma Surgeen2026-05-15T10:00:00.000ZWomen’s Health Investment: Rhetoric vs. Realityhttps://www.pharmaradar360.com/article/1da6721ccea0417bPharma Surgeen2026-05-15T09:36:45.000ZHI-TAC: Karina Yaniv Appointed as New Scientific Directorhttps://www.pharmaradar360.com/article/123a6a9ac07d10d3Pharma Surgeen2026-05-15T09:22:11.000ZOutstanding nursing and midwifery staff celebratedhttps://www.pharmaradar360.com/article/5134cf80bedc135ePharma Surgeen2026-05-15T09:19:33.000ZThree PsA trials to watch in 2026https://www.pharmaradar360.com/article/d976e305286eb8aaPharma Surgeen2026-05-15T09:02:54.000ZNHSGGC Statement – Red Wing Medical Practicehttps://www.pharmaradar360.com/article/6501dc7483256e53Pharma Surgeen2026-05-15T09:01:07.000ZUniversity of Oxford secures two International Cardiovascular Research Partnership Awardshttps://www.pharmaradar360.com/article/d33f3e8d7996e745Pharma Surgeen2026-05-15T09:00:09.000ZDNA‑Guided CRISPR Suggests a New Direction for RNA Editinghttps://www.pharmaradar360.com/article/bfe909f8d69db17dPharma Surgeen2026-05-15T08:45:18.000ZMassive Bio and Just Worldwide to expand cancer trial accesshttps://www.pharmaradar360.com/article/4d97cce944075cacPharma Surgeen2026-05-15T08:42:45.000ZKyowa Kirin secures FDA approval for Crysvita dosing updatehttps://www.pharmaradar360.com/article/e64a0c1b456aba2dPharma Surgeen2026-05-15T08:41:11.000ZUniversität Heidelberg Successful with Application for Collaborative Research Centrehttps://www.pharmaradar360.com/article/83cd153da6f8425fPharma Surgeen2026-05-15T08:30:00.000ZECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long termhttps://www.pharmaradar360.com/article/b2d3850b163222a5Pharma Surgeen2026-05-15T08:16:32.000ZCough & coldhttps://www.pharmaradar360.com/article/a8497e466877a7c9Pharma Surgeen2026-05-15T08:16:32.000ZPain managementhttps://www.pharmaradar360.com/article/4b4cd55fa1dd6689Pharma Surgeen2026-05-15T08:16:32.000ZNeurologyhttps://www.pharmaradar360.com/article/c0aff89e19d3cc93Pharma Surgeen2026-05-15T08:16:32.000ZCardiometabolichttps://www.pharmaradar360.com/article/47d337344087a4b0Pharma Surgeen2026-05-15T08:16:32.000ZIntim healthhttps://www.pharmaradar360.com/article/1caa88924c198621Pharma Surgeen2026-05-15T08:16:32.000ZGastroenterologyhttps://www.pharmaradar360.com/article/8fd9d23cc9e52abdPharma Surgeen2026-05-15T08:16:32.000ZSkin carehttps://www.pharmaradar360.com/article/53725b9002e42bccPharma Surgeen2026-05-15T08:16:32.000ZAntibiotics and antisepticshttps://www.pharmaradar360.com/article/d690ddf58d90c0d1Pharma Surgeen2026-05-15T08:16:32.000ZDrugs for Allergyhttps://www.pharmaradar360.com/article/066270a6295f5fadPharma Surgeen2026-05-15T08:16:32.000ZПрепарати від застуди та температуриhttps://www.pharmaradar360.com/article/f69bf9fb8c4ddf62Pharma Surgeen2026-05-15T08:16:32.000ZПрепарати від болю та запаленняhttps://www.pharmaradar360.com/article/0947fef84bc72938Pharma Surgeen2026-05-15T08:16:32.000ZНеврологічні препаратиhttps://www.pharmaradar360.com/article/aaa1bfa1c28e4363Pharma Surgeen2026-05-15T08:16:32.000ZКардіометаболічні препаратиhttps://www.pharmaradar360.com/article/dd4d70aaafbb7a6dPharma Surgeen2026-05-15T08:16:32.000ZПрепарати для інтимного здоров'яhttps://www.pharmaradar360.com/article/18af2a5c870c72f3Pharma Surgeen2026-05-15T08:16:32.000ZПрепарати для застосування у хірургіїhttps://www.pharmaradar360.com/article/ae82bbdf59d1be37Pharma Surgeen2026-05-15T08:16:32.000ZГастроентерологічні препаратиhttps://www.pharmaradar360.com/article/02066fd3fd616cdcPharma Surgeen2026-05-15T08:16:32.000ZДерматологічні препаратиhttps://www.pharmaradar360.com/article/0a091f728bc89826Pharma Surgeen2026-05-15T08:16:32.000ZАнтибактеріальні препарати та антисептикиhttps://www.pharmaradar360.com/article/51ea0cec05c70620Pharma Surgeen2026-05-15T08:16:32.000ZПрепарати при алергіїhttps://www.pharmaradar360.com/article/f5ed25629a28b133Pharma Surgeen2026-05-15T08:16:32.000ZПрепаратиhttps://www.pharmaradar360.com/article/e2a29d0aae4df370Pharma Surgeen2026-05-15T08:13:07.000ZCHE Ranking 2026: The University of Freiburg receives top ratingshttps://www.pharmaradar360.com/article/9901772df474da6dPharma Surgeen2026-05-15T08:13:00.000ZHeidelberger Sonderforschungsbereich „Molekulare Schaltkreise von Herzerkrankungen“ verlängerthttps://www.pharmaradar360.com/article/54fcb31cf3af8e5fPharma Surgeen2026-05-15T08:00:56.000ZNew wound research to tackle pain and cost of chronic woundshttps://www.pharmaradar360.com/article/7580f5505994c5c2Pharma Surgeen2026-05-15T08:00:00.000ZFreeze variability, not progress: strengthen your cell therapy supply chain from the starthttps://www.pharmaradar360.com/article/cc3900b201e24e09Pharma Surgeen2026-05-15T07:30:09.000ZUpdate for Jitendra Narayanhttps://www.pharmaradar360.com/article/1383c7b7a666d019Pharma Surgeen2026-05-15T07:30:00.000ZThe Clínic-IDIBAPS participates in the second EASL-Lancet Commission report calling for urgent action against liver diseases in Europehttps://www.pharmaradar360.com/article/eee948bf62d61991Pharma Surgeen2026-05-15T07:21:52.000ZSupreme Court preserves mail access for abortion pillhttps://www.pharmaradar360.com/article/4791fd606d6f12eaPharma Surgeen2026-05-15T07:15:07.000ZMed nål och tråd skapar Eva-Britt Hägg individuellt stöd till patienterhttps://www.pharmaradar360.com/article/003aaa891001b496Pharma Surgeen2026-05-15T07:03:00.000ZIm Portrait: Dr. Christina Mertenshttps://www.pharmaradar360.com/article/00d699d34ace992aPharma Surgeen2026-05-15T07:00:00.000ZUNMC, UNK celebrate opening of rural health education complexhttps://www.pharmaradar360.com/article/baa2d14f65059ffaPharma Surgeen2026-05-15T07:00:00.000ZRight medicine, right person: Jacintha Sivarajah on science with purposehttps://www.pharmaradar360.com/article/a1ae22af4d676949Pharma Surgeen2026-05-15T06:58:00.000ZPre-Dental Day a big success for UNMC student organizershttps://www.pharmaradar360.com/article/bad9baae2c13ebf7Pharma Surgeen2026-05-15T06:56:00.000ZApplications open for Interprofessional Academy of Educatorshttps://www.pharmaradar360.com/article/1d4b70dae0c2562dPharma Surgeen2026-05-15T06:52:00.000ZUNMC for the record, May 15, 2026https://www.pharmaradar360.com/article/37ce8493b4383751Pharma Surgeen2026-05-15T06:49:12.000ZAttenzione alle telefonate sospettehttps://www.pharmaradar360.com/article/d22fac740d71a281Pharma Surgeen2026-05-15T06:48:18.000ZGuy’s and St Thomas’ strengthens partnership with London South Bank University to support NHS workforcehttps://www.pharmaradar360.com/article/108e61e3c0c4e555Pharma Surgeen2026-05-15T06:30:09.000ZJames Murray appointed health secretaryhttps://www.pharmaradar360.com/article/219c0d94c77030a4Pharma Surgeen2026-05-15T06:04:24.000ZEn Lo Contador se iniciaron jornadas de diálogo en los campus en torno al Plan Estratégico UChttps://www.pharmaradar360.com/article/12fd7bfc2b41f898Pharma Surgeen2026-05-15T06:02:43.000ZDavid Schönach will defend his PhD thesishttps://www.pharmaradar360.com/article/c3cc04a96e501837Pharma Surgeen2026-05-15T05:42:44.000ZAmerican College of Radiology urges FDA to address breast biopsy needle shortageshttps://www.pharmaradar360.com/article/c7a403169d63b770Pharma Surgeen2026-05-15T05:39:41.000ZUnitedHealthcare seeks nearly 8% premium hike in 1 state, blaming rising radiology costshttps://www.pharmaradar360.com/article/4b4fba8322cd7ae2Pharma Surgeen2026-05-15T05:36:43.000Z2026年度 東北大学ジャパンバイオデザインフェローシッププログラム開講式を執り行いましたhttps://www.pharmaradar360.com/article/fba189a72dc8d238Pharma Surgeen2026-05-15T05:27:18.000ZRadiologist must pay $14,000 fine, undergo training after allegedly overlooking abnormalities on brain scanhttps://www.pharmaradar360.com/article/56cf48ddcc0b4115Pharma Surgeen2026-05-15T05:06:21.000ZOne Day at a Time: FDA’s New AI-Informed Inspection Pilot and What It Means for Industryhttps://www.pharmaradar360.com/article/5c3bb4d32bf6a39fPharma Surgeen2026-05-15T04:50:11.000ZA grad student’s wild idea sparks a major aging breakthroughhttps://www.pharmaradar360.com/article/5cf02d03bbe82010Pharma Surgeen2026-05-15T04:15:26.000ZA 47-year study reveals when strength and fitness start to fadehttps://www.pharmaradar360.com/article/fdf2b43304c40185Pharma Surgeen2026-05-15T03:46:00.000ZAlumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospectshttps://www.pharmaradar360.com/article/7c45c96ecf7d7a9dPharma Surgeen2026-05-15T03:00:00.000Z[SHINSA]English Translation of Review Report: Setaneohttps://www.pharmaradar360.com/article/5013b9e7e4936272Pharma Surgeen2026-05-15T02:30:00.000ZNotice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executiveshttps://www.pharmaradar360.com/article/5e192b756f5bffa2Pharma Surgeen2026-05-15T02:30:00.000ZNotice Regarding Continuation of the Performance-linked Stock Compensation Schemehttps://www.pharmaradar360.com/article/37738bc25342c6f1Pharma Surgeen2026-05-15T01:52:00.000ZAardvark to dig into phase 3 data early after FDA imposes holdhttps://www.pharmaradar360.com/article/f0aeeb6d963c6203Pharma Surgeen2026-05-15T01:33:08.000ZThe key ingredients of a successful radiologist-wellness initiativehttps://www.pharmaradar360.com/article/131eb6d204046f1cPharma Surgeen2026-05-15T01:32:29.000ZIniciativa “Viaje del estudiante” acompañará a alumnos en hitos clave de su vida universitariahttps://www.pharmaradar360.com/article/4a5e3a5826e951e3Pharma Surgeen2026-05-15T00:50:57.000ZColon cancer is rising in young adults and doctors don’t fully know whyhttps://www.pharmaradar360.com/article/5687d0d351605c04Pharma Surgeen2026-05-15T00:00:00.000ZAutism subtypes identified using cross-species functional connectivity analyseshttps://www.pharmaradar360.com/article/112418dfee5e72a1Pharma Surgeen2026-05-15T00:00:00.000ZExcitatory synapses onto axonic spines jump-start action potentials and route information flowhttps://www.pharmaradar360.com/article/60f5ddc8b070e13bPharma Surgeen2026-05-15T00:00:00.000ZParsing autism spectrum heterogeneity through fMRIhttps://www.pharmaradar360.com/article/893bffcaa36350c9Pharma Surgeen2026-05-15T00:00:00.000ZWhat Galen’s dissections reveal about tacit learning in modern medical educationhttps://www.pharmaradar360.com/article/4ba617e385cc7884Pharma Surgeen2026-05-15T00:00:00.000ZPopulation-scale genomic medicine with the Hong Kong Genome Projecthttps://www.pharmaradar360.com/article/88d19748d4ba5af2Pharma Surgeen2026-05-15T00:00:00.000ZFavipiravir for Lassa fever: an open-label, randomized controlled phase 2 trialhttps://www.pharmaradar360.com/article/006116c742604a76Pharma Surgeen2026-05-15T00:00:00.000ZGenetic survey exposes flaws in widely used mouse modelshttps://www.pharmaradar360.com/article/0872fcf7cb03dcf7Pharma Surgeen2026-05-15T00:00:00.000ZEven mild blows to the head disrupt the microbiomehttps://www.pharmaradar360.com/article/a38395e648b15e56Pharma Surgeen2026-05-15T00:00:00.000ZRunning a farm, pursuing a research career: what’s the difference?https://www.pharmaradar360.com/article/d83a6ca0b4ac4c26Pharma Surgeen2026-05-15T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/0f2a097306fdfe37Pharma Surgeen2026-05-15T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/c22feb44ee735394Pharma Surgeen2026-05-15T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/08e209ac35d14948Pharma Surgeen2026-05-15T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/f5eb27f36c3ce1aePharma Surgeen2026-05-15T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/e4a9bb975c0a1f47Pharma Surgeen2026-05-15T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/13c6242141d17ffaPharma Surgeen2026-05-15T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/f9ef11d6dfffe9c9Pharma Surgeen2026-05-15T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/b4e662c7afec9fe8Pharma Surgeen2026-05-15T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/af73045a3cc52572Pharma Surgeen2026-05-15T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/f20b68ea1032a736Pharma Surgeen2026-05-15T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/3ce949a03dc1cda4Pharma Surgeen2026-05-15T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/51ce9aaec94000d4Pharma Surgeen2026-05-15T00:00:00.000Z6203https://www.pharmaradar360.com/article/1d0d76f798eb8351Pharma Surgeen2026-05-15T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/1d75c70065f40187Pharma Surgeen2026-05-15T00:00:00.000ZARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Updatehttps://www.pharmaradar360.com/article/af0acb28bb7ab581Pharma Surgeen2026-05-14T23:30:00.000ZChina’s National Medical Products Administration Accepts New Drug Application for IZERVAY™ (avacincaptad pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degenerationhttps://www.pharmaradar360.com/article/2b07d29b4f58289ePharma Surgeen2026-05-14T23:21:10.000ZBest of ASCO 2026 in Japan開催のご案内https://www.pharmaradar360.com/article/d64c3a788e92c473Pharma Surgeen2026-05-14T21:56:47.000ZNew radiopharmaceutical achieves remission in difficult-to-treat pancreatic cancerhttps://www.pharmaradar360.com/article/a9e837c11b943994Pharma Surgeen2026-05-14T21:40:00.000ZImplantable Living Materials Contain Infection-Sensing Bacteria That Release Therapeuticshttps://www.pharmaradar360.com/article/6ca8bd5388278a87Pharma Surgeen2026-05-14T21:09:58.000ZPollen Allergies Are Brutal This Year – A Doctor Explains Why, and How to Find Reliefhttps://www.pharmaradar360.com/article/2c14988ae8694ddePharma Surgeen2026-05-14T21:00:49.000Z19th Annual Meeting of the Korean Society of Medical Oncology（KSMO2026）開催のご案内https://www.pharmaradar360.com/article/887acce9020da7d3Pharma Surgeen2026-05-14T21:00:03.000ZAnswers are in our DNA™https://www.pharmaradar360.com/article/1c3221788566127dPharma Surgeen2026-05-14T20:42:37.000ZCEDETi UC y Fundación Rassmuss desarrollan innovador test para abordar brechas de lecturahttps://www.pharmaradar360.com/article/5c274fdfaa7af741Pharma Surgeen2026-05-14T20:40:59.000ZSponsor’s Guide to IRB Approval (Part IV): Preparing IRB Documents That Prevent Delayshttps://www.pharmaradar360.com/article/98eca7fb50a63117Pharma Surgeen2026-05-14T20:35:12.000ZDr. Andrew Lewis Featured In BioPharm International: Why AI Fails in Drug Development and How to Build Tools That Actually Deliver Real Valuehttps://www.pharmaradar360.com/article/2ba8d6d358781344Pharma Surgeen2026-05-14T20:34:00.000ZIDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Dayhttps://www.pharmaradar360.com/article/f019f1286b1fd341Pharma Surgeen2026-05-14T20:20:01.000ZQ&A with Advarra’s Associate Director of Client Success Evan Sanderhttps://www.pharmaradar360.com/article/2e002588f86991e2Pharma Surgeen2026-05-14T20:15:33.000ZMedicaid Changes in House and Senate Reconciliation Bills Would Increase Costs for 1.3 Million Low-Income Medicare Beneficiarieshttps://www.pharmaradar360.com/article/04baebe9cc278c87Pharma Surgeen2026-05-14T20:06:41.000ZZymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stockhttps://www.pharmaradar360.com/article/829a2b2d19e7bd2dPharma Surgeen2026-05-14T19:54:00.000ZOverview of President Trump’s Executive Actions Impacting LGBTQ+ Healthhttps://www.pharmaradar360.com/article/d559b1efb86a3f26Pharma Surgeen2026-05-14T19:06:03.000ZBeyond the Border: A Global Learning Experiencehttps://www.pharmaradar360.com/article/5af918e9e3e1a98cPharma Surgeen2026-05-14T18:50:34.000Z#ASGCT26: Encoded's gene therapy reduced seizures in Dravet syndromehttps://www.pharmaradar360.com/article/d6e0c4bd1c58f67aPharma Surgeen2026-05-14T18:50:13.000ZPharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovihttps://www.pharmaradar360.com/article/70f2c64ad3f658cePharma Surgeen2026-05-14T18:45:37.000ZMolecular Anchors Help Tumor Therapies Stay Longer on Cancer Cellshttps://www.pharmaradar360.com/article/f9ed165f5db680b3Pharma Surgeen2026-05-14T18:31:00.000ZUNMC, UNK celebrate opening of rural health education complexhttps://www.pharmaradar360.com/article/5f9a8e2893a3d9b3Pharma Surgeen2026-05-14T18:30:00.000ZTransforming Clinical Trial Design and Avoiding AI Wrappers: Q&A with Angela Schwabhttps://www.pharmaradar360.com/article/e87206f0468f9c04Pharma Surgeen2026-05-14T18:24:17.000Z#ASGCT26 dispatch: In vivo CAR-T is everywherehttps://www.pharmaradar360.com/article/7dab46499f9458a3Pharma Surgeen2026-05-14T18:23:07.000ZMIMM Bites – May Newsletter 2026https://www.pharmaradar360.com/article/f70b7d5a6de02d57Pharma Surgeen2026-05-14T18:22:42.000ZCon nuevas obras de puesta en valor, el histórico Museo recupera toda su luzhttps://www.pharmaradar360.com/article/c6741008ebaebcb7Pharma Surgeen2026-05-14T18:20:56.000ZMarcha federal por la Universidad Públicahttps://www.pharmaradar360.com/article/efdde648713e8c87Pharma Surgeen2026-05-14T18:20:22.000ZMarcha Universitaria: facilidades académicas y administrativas en la UNLPhttps://www.pharmaradar360.com/article/18906c3c91c7338aPharma Surgeen2026-05-14T18:11:50.000ZEdward Fon appointed Director of The Neuro at McGill University and the MUHC-Santé Québec, and Chief of the Neuroscience Mission at MUHC-Santé Québechttps://www.pharmaradar360.com/article/7349a01fcb47eb3aPharma Surgeen2026-05-14T18:06:14.000ZLa Catedra UNESCO de la UNLP presentó el seminario internacional “Economía, Derechos Humanos y Orden internacional en Peligro: Desafíos y Oportunidades entre Italia y Argentina”https://www.pharmaradar360.com/article/7afa1de8e5767e8aPharma Surgeen2026-05-14T18:01:25.000Z12 de mayo 2026 – “Economía y Derechos Humanos”, la Catedra UNESCO de la UNLP propone declarar el tema de interés provincial por la Honorable Cámara de la Provincia de Buenos Aireshttps://www.pharmaradar360.com/article/81052fb94f3e3051Pharma Surgeen2026-05-14T18:00:00.000ZLocal businesswoman and mom raises awareness and funds to end women’s No. 1 health threathttps://www.pharmaradar360.com/article/6dfe1fe7b5fe2c61Pharma Surgeen2026-05-14T17:53:21.000ZThe ‘velocity of obesity’ aims to show which nations are slowing an epidemichttps://www.pharmaradar360.com/article/2466cc57c5016193Pharma Surgeen2026-05-14T17:49:34.000ZHey Minnesotans, want a wellness boost? Seek out a Sound Garden.https://www.pharmaradar360.com/article/69ffce3756b12549Pharma Surgeen2026-05-14T17:42:15.000ZThe (Literal) Pulsing Heart of Medtronic’s Relationship with the University of Minnesotahttps://www.pharmaradar360.com/article/bf7d86e0942815a7Pharma Surgeen2026-05-14T16:59:19.000ZAI is No Longer the Bottleneck: Why Clinical Development Must Shift from Innovation to Executionhttps://www.pharmaradar360.com/article/50f1db08205612b7Pharma Surgeen2026-05-14T16:55:27.000ZIt’s A Fact: Sharing Clinical Trial Results With Participants Builds Trusthttps://www.pharmaradar360.com/article/9b90965593fc384ePharma Surgeen2026-05-14T16:55:13.000ZWhy 75 Top Pharma Execs Are Ditching Fragmented Marketing Stackshttps://www.pharmaradar360.com/article/c01d54fcb421710aPharma Surgeen2026-05-14T16:14:00.000ZChutes & Ladders—AC Immune CEO bids adieuhttps://www.pharmaradar360.com/article/02cffee56d13b228Pharma Surgeen2026-05-14T16:10:53.000ZDean’s message: Facing transitions, new trials and forging aheadhttps://www.pharmaradar360.com/article/71a958f8225a1fb6Pharma Surgeen2026-05-14T16:02:35.000ZCORMEDIX THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEhttps://www.pharmaradar360.com/article/04b8f936d27a20a4Pharma Surgeen2026-05-14T16:00:16.000ZDrugmakers have to go through rigorous tests to get a lower tariff ratehttps://www.pharmaradar360.com/article/c209987c55df6d4aPharma Surgeen2026-05-14T16:00:00.000ZThe Prior Authorization System Fails Patients. There's a Better Wayhttps://www.pharmaradar360.com/article/32282ccb9f10489fPharma Surgeen2026-05-14T16:00:00.000ZUSPTO doubles down on inconsistencies in dual IPR-court actionhttps://www.pharmaradar360.com/article/51fb1ad36b7de2c5Pharma Surgeen2026-05-14T15:54:30.000ZIMP Release and Supply Management: Ensuring Compliance from Manufacture to Sitehttps://www.pharmaradar360.com/article/0b71ccb77f109818Pharma Surgeen2026-05-14T15:33:34.000ZECO 2026: ATTAIN-MAINTAIN trial showcases orforglipron’s role in sustained weight losshttps://www.pharmaradar360.com/article/b74589bdd6fa6f9fPharma Surgeen2026-05-14T15:31:58.000ZNew medical faculty, May 2026https://www.pharmaradar360.com/article/152f965481be2a1dPharma Surgeen2026-05-14T15:30:00.000Zヒト化抗CD20モノクローナル抗体「ガザイバ」 特発性ネフローゼ症候群に対して適応拡大申請https://www.pharmaradar360.com/article/10be21253abedbb0Pharma Surgeen2026-05-14T15:25:51.000ZQuan Ly, MD, named to ACS workforce grouphttps://www.pharmaradar360.com/article/1ff0ca067ed14ea3Pharma Surgeen2026-05-14T15:22:03.000ZDirección de Asuntos Municipaleshttps://www.pharmaradar360.com/article/62288295f584b001Pharma Surgeen2026-05-14T15:20:11.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: 1115-waivershttps://www.pharmaradar360.com/article/1ba03fb194a2b2e3Pharma Surgeen2026-05-14T15:19:50.000ZTracking Implementation of the 2025 Reconciliation Law Medicaid Work Requirements: Related Resourceshttps://www.pharmaradar360.com/article/52e7d9d84b91955fPharma Surgeen2026-05-14T15:19:26.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Implementation Questionshttps://www.pharmaradar360.com/article/987f1416282e67a9Pharma Surgeen2026-05-14T15:16:09.000ZPodcast: UK targets speedy clinical trial set-ups with 150-day benchmarkhttps://www.pharmaradar360.com/article/09ff969b42a53074Pharma Surgeen2026-05-14T15:13:01.000ZAOA inducts 48 new UNMC student, resident and faculty membershttps://www.pharmaradar360.com/article/c68675550e6284b2Pharma Surgeen2026-05-14T15:09:36.000ZECO 2026: survodutide delivers renal and metabolic benefits in DKD modelhttps://www.pharmaradar360.com/article/5f9d6d519c6d3b6dPharma Surgeen2026-05-14T15:03:14.000ZMulti-Stakeholder Hearing for the 2026 UN High-Level Meeting on HIV/AIDShttps://www.pharmaradar360.com/article/d938d20ecf2042f6Pharma Surgeen2026-05-14T15:03:05.000ZW. M. Keck Foundation gives $1.2 million to UC Irvine to support early-career scientistshttps://www.pharmaradar360.com/article/2e53dd5281d35534Pharma Surgeen2026-05-14T14:58:59.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/3be8b6f65fa9c8dePharma Surgeen2026-05-14T14:42:33.000ZDegron, CREATE, TenNor raise capital; Cabaletta posts CAR-T datahttps://www.pharmaradar360.com/article/0be91df55cb9775cPharma Surgeen2026-05-14T14:40:01.000ZHow tissues tune immune responses to match the threathttps://www.pharmaradar360.com/article/392aa6275dfa3574Pharma Surgeen2026-05-14T14:34:06.000ZComplications of Temporary Transvenous Cardiac Pacing by Access Site: A Systematic Review and Meta‐Analysishttps://www.pharmaradar360.com/article/20e20577a17d5f77Pharma Surgeen2026-05-14T14:32:01.000ZRecurrent Takotsubo Syndrome After Pacemaker Implantationhttps://www.pharmaradar360.com/article/9a66e889a8d8bf7aPharma Surgeen2026-05-14T14:31:59.000ZAstraZeneca follows Merck with Phase 3 win in bladder cancerhttps://www.pharmaradar360.com/article/b8bbd465947fb3e1Pharma Surgeen2026-05-14T14:22:46.000ZScientists say a daily multivitamin may help slow aginghttps://www.pharmaradar360.com/article/e1e1422fe0475628Pharma Surgeen2026-05-14T14:22:19.000ZUK health secretary Wes Streeting resignshttps://www.pharmaradar360.com/article/da3c8d94cf452174Pharma Surgeen2026-05-14T14:21:01.000ZUK health secretary Wes Streeting resignshttps://www.pharmaradar360.com/article/29385c61a171ce14Pharma Surgeen2026-05-14T14:12:00.000ZBipartisan lawmakers reintroduce bill barring PBMs from owning pharmacieshttps://www.pharmaradar360.com/article/b286def5096cb37ePharma Surgeen2026-05-14T14:10:18.000ZMacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attackhttps://www.pharmaradar360.com/article/6ac7d0b99e08fb62Pharma Surgeen2026-05-14T14:04:00.000ZEpic, Oracle and Cleveland Clinic among companies to joining CMS prior authorization initiativehttps://www.pharmaradar360.com/article/fa5808c79d706759Pharma Surgeen2026-05-14T14:00:00.000ZEncoding performance of cortical neurons critically depends on their morphological and neurophysiological propertieshttps://www.pharmaradar360.com/article/221f6ef188f3210fPharma Surgeen2026-05-14T14:00:00.000ZStructural basis for hemoglobin scavenging by CD163 reveals mechanism of ligand promiscuityhttps://www.pharmaradar360.com/article/42f607b6f24764bbPharma Surgeen2026-05-14T14:00:00.000ZBeyond survival: Redefining successful aging in the era of medical complexityhttps://www.pharmaradar360.com/article/658fd508c2c6d93cPharma Surgeen2026-05-14T13:55:02.000ZWelcome to the inaugural edition of The BEAT from HeartSciences.https://www.pharmaradar360.com/article/9a152d515b20d413Pharma Surgeen2026-05-14T13:49:48.000ZShionogi weighs future of FXS drug after double Phase III misshttps://www.pharmaradar360.com/article/8c46b0c446956343Pharma Surgeen2026-05-14T13:44:02.000ZRECORDATI: PUBLICATION OF THE INTERIM REPORT AS AT 31.03.2026 AND OF THE MINUTES OF THE SHAREHOLDERS’ MEETING DATED 29.04.2026https://www.pharmaradar360.com/article/97c4daaa407d041bPharma Surgeen2026-05-14T13:34:24.000ZPathAI’s AISight® Dx IMS Platform Supports the AISight Consults Workflow for Streamlined Digital Consult Managementhttps://www.pharmaradar360.com/article/31c054403c2aca3bPharma Surgeen2026-05-14T13:26:00.000ZCourt approves sale of CVS' Omnicare unit to GenieRx Holdingshttps://www.pharmaradar360.com/article/431e98b1f8fbc67dPharma Surgeen2026-05-14T13:23:29.000ZFDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclaxhttps://www.pharmaradar360.com/article/cd501b0484ab2aa8Pharma Surgeen2026-05-14T13:22:37.000ZANMAT incorpora nueva Resolución del Grupo Mercado Común para adecuar normativa a los nuevos estándares del Mercosurhttps://www.pharmaradar360.com/article/35ebd1b9d59faaa2Pharma Surgeen2026-05-14T13:22:07.000ZTreatment shift needed for brittle bone diseasehttps://www.pharmaradar360.com/article/d4b7ec0e1b861916Pharma Surgeen2026-05-14T13:12:37.000ZTwins with Batten disease benefit from UNC Health drug trialhttps://www.pharmaradar360.com/article/74e5947a40879c7ePharma Surgeen2026-05-14T13:00:56.000ZViz.ai Launches Viz Pulmonary Suite, the First Comprehensive AI-Powered Solution Dedicated to Pulmonary Care Deliveryhttps://www.pharmaradar360.com/article/5f861c2c2694e450Pharma Surgeen2026-05-14T13:00:56.000ZHow Penn Medicine plans to use AI to train their doctorshttps://www.pharmaradar360.com/article/2bd58c6448ff9b75Pharma Surgeen2026-05-14T13:00:00.000ZBeyond the Molecule: The New Competitive Battlefield in Oncologyhttps://www.pharmaradar360.com/article/22806af428cdfbaaPharma Surgeen2026-05-14T13:00:00.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirements Data and Policieshttps://www.pharmaradar360.com/article/8c88978aac3f447ePharma Surgeen2026-05-14T13:00:00.000ZTracking Implementation of the 2025 Reconciliation Law: Medicaid Work Requirementshttps://www.pharmaradar360.com/article/a92e986b31ad9c6bPharma Surgeen2026-05-14T13:00:00.000ZA Look at New or Expanded Medicaid and Public Health Partnerships from 2025: Findings from A Survey of State Medicaid Programshttps://www.pharmaradar360.com/article/43cddc085c6efc42Pharma Surgeen2026-05-14T12:30:21.000ZTempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neurosciencehttps://www.pharmaradar360.com/article/daaf09a2ca0196a2Pharma Surgeen2026-05-14T12:30:06.000ZHealth secretary Wes Streeting resigns after losing faith in PMhttps://www.pharmaradar360.com/article/fc8a27adc18977e6Pharma Surgeen2026-05-14T12:13:00.000ZSignant Health buys Ametris to unite data streams in clinical trialshttps://www.pharmaradar360.com/article/4bdf7a119ff5bf52Pharma Surgeen2026-05-14T12:09:55.000ZGraduate School announces 2026 Impact Award winnershttps://www.pharmaradar360.com/article/85daac1165b1c481Pharma Surgeen2026-05-14T12:05:57.000ZApyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuctionhttps://www.pharmaradar360.com/article/fa5b94d0a77afe9dPharma Surgeen2026-05-14T12:02:08.000ZHantavirus: una amenaza silenciosahttps://www.pharmaradar360.com/article/c596707020e5f93fPharma Surgeen2026-05-14T12:00:00.000ZPredicting typhoon intensity using ocean surface temperatureshttps://www.pharmaradar360.com/article/703e1b8864fe6808Pharma Surgeen2026-05-14T12:00:00.000ZBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Updatehttps://www.pharmaradar360.com/article/15cb7aae6682a80ePharma Surgeen2026-05-14T11:56:46.000ZANMAT no intervendrá en los trámites de solicitud de Autorización de Importación/ Exportación de productos con SOMATROPINAhttps://www.pharmaradar360.com/article/69a7bb3b7020a03aPharma Surgeen2026-05-14T11:52:07.000ZMolecules emerge as a new kind of building block for quantum computershttps://www.pharmaradar360.com/article/c485f4b6f432217cPharma Surgeen2026-05-14T11:34:00.000ZEli Lilly delivers $50M boost to UNICEF’s pediatric health pushhttps://www.pharmaradar360.com/article/e14fe1ab303b8fb0Pharma Surgeen2026-05-14T11:32:28.000ZBiogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacyhttps://www.pharmaradar360.com/article/a59159619c2a23bfPharma Surgeen2026-05-14T11:30:00.000ZKFF Poll Finds That Most Adults Lack Confidence in Key Health Agencies to Act Independently — The Monitorhttps://www.pharmaradar360.com/article/e9110d9f8d781527Pharma Surgeen2026-05-14T11:16:56.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Marzo de 2026https://www.pharmaradar360.com/article/4e840a726b6843f6Pharma Surgeen2026-05-14T11:09:33.000ZTied up in the Lab: An Unexpected Catheter Knot in the Arterial Systemhttps://www.pharmaradar360.com/article/26e70f3dac539dc5Pharma Surgeen2026-05-14T11:05:11.000ZRegulatory round-up: A month of key FDA approvals for cancer drugshttps://www.pharmaradar360.com/article/ad33bf0677e4fbf7Pharma Surgeen2026-05-14T11:05:01.000ZShort‐Term, Weight‐Adjusted Colchicine to Prevent Post‐CABG Arrhythmias: A Randomized, Double‐Blind, Controlled Trialhttps://www.pharmaradar360.com/article/ac91b14c84164354Pharma Surgeen2026-05-14T11:01:55.000ZImfinzi set to become first immunotherapy for stomach cancer patients on NHShttps://www.pharmaradar360.com/article/f846f6b748856b39Pharma Surgeen2026-05-14T11:01:30.000ZECO 2026: gut hormone signals differ in T1D with obesityhttps://www.pharmaradar360.com/article/511bf182aa23b468Pharma Surgeen2026-05-14T11:00:17.000ZRegenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalhttps://www.pharmaradar360.com/article/bd8941ecef5ab71cPharma Surgeen2026-05-14T11:00:00.000ZTiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumabhttps://www.pharmaradar360.com/article/6fa75b549a23ca12Pharma Surgeen2026-05-14T11:00:00.000ZCanada nabs time on Extremely Large Telescope with groundbreaking instrument investmenthttps://www.pharmaradar360.com/article/8c37ca7058d15441Pharma Surgeen2026-05-14T11:00:00.000ZLilly and UNICEF collaborate to give millions of children a healthier starthttps://www.pharmaradar360.com/article/4518c3165d1d7f92Pharma Surgeen2026-05-14T10:50:00.000ZAstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytrudahttps://www.pharmaradar360.com/article/47ae2ccef3b38f85Pharma Surgeen2026-05-14T10:47:00.000ZBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?https://www.pharmaradar360.com/article/c0cb779a544dcdd4Pharma Surgeen2026-05-14T10:47:00.000ZBiopharma leaders rally behind Pazdur for FDA commissioner pick. But does he want the role?https://www.pharmaradar360.com/article/87fd130533d9037fPharma Surgeen2026-05-14T10:35:10.000ZZydus to acquire Assertio in $166m dealhttps://www.pharmaradar360.com/article/bbb689d5fe14b5c1Pharma Surgeen2026-05-14T10:31:51.000ZBeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclextahttps://www.pharmaradar360.com/article/c3de1aa3e383a5e0Pharma Surgeen2026-05-14T10:30:00.000ZDigital Health Coffee Time Briefing ☕https://www.pharmaradar360.com/article/dccf20beaf9ecd41Pharma Surgeen2026-05-14T10:30:00.000ZHenry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth